Seres Therapeutics (MCRB) Other Accumulated Expenses (2014 - 2026)

Seres Therapeutics has reported Other Accumulated Expenses for 13 years, with the latest figure at $644000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 75.54% year-over-year to $644000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $644000.0 (down 75.54% YoY) and the FY2025 annual result came in at $896000.0, down 58.58% from the prior year.
• Other Accumulated Expenses retreated to $644000.0 in Q1 2026 per MCRB's latest filing, from $896000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $8.0 million in Q2 2023 and troughed at $644000.0 in Q1 2026.
• A 5-year average of $3.3 million and a median of $2.8 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses soared 348.03% in 2023, then sank 77.38% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $3.6 million in 2022, then decreased by 23.93% to $2.8 million in 2023, then retreated by 21.97% to $2.2 million in 2024, then slumped by 58.58% to $896000.0 in 2025, then declined by 28.12% to $644000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $644000.0, $896000.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.